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ABSTRACT
Background and Objectives: Although the popularity of
robotic-assisted laparoscopic prostatectomy is assured, lit-
tle is known about the oncologic outcomes following the
procedure.
Methods: We performed a retrospective cohort study
including consecutive patients who underwent the sur-
gery between 2003 and 2007 with at least 6 months of
follow-up (n464). Patients were stratified into low-, in-
termediate-, and high-risk groups according to D’Amico
criteria. Biochemical failure was defined as a PSA 0.2
ng/mL.
Results: Of study patients, 256 (55%), 171 (37%), and 37
(8%) were classified as low-, intermediate-, and high-risk,
respectively. Over a mean follow-up of 14.1 months
(range, 6.0 to 55.3), 7.3% experienced biochemical failure.
Biochemical disease-free survival at 30 months was 94%,
79%, and 73% among patients in the low-, intermediate-,
and high-risk groups, respectively, (P0.001). Preopera-
tive risk stratification was strongly associated with bio-
chemical failure, with hazard ratios of 5.04 (95%: 1.52 to
16.7; P0.001) and 7.04 (95%: 1.39 to 35.6; P  0.001) for
intermediate- and high- over low-risk groups, respec-
tively. The ability of risk stratification to predict biochem-
ical failure had an area under the receiver operator char-
acteristic curve of 0.74.
Conclusion: Robotic prostatectomy provides excellent
cancer control outcomes for clinically localized disease.
Key Words: Prostatic neoplasms, Prostatectomy, Out-
come assessment, Robotics.
INTRODUCTION
The American Cancer Society estimated that 186 320 new
prostate cancer cases would be diagnosed in 2008, mak-
ing it the most common form of cancer in men.1 Because
treatment of localized prostate cancer can be curative,
accurate preoperative risk stratification is paramount in
choosing optimal treatment. In 1998, D’Amico et al2 ret-
rospectively examined the outcomes of a large cohort of
men with prostate cancer who underwent open radical
prostatectomy, external beam radiation, and interstitial
radiation with or without neoadjuvant androgen depriva-
tion. The authors proposed a risk stratification scheme
based on preoperative Gleason sum, prostatic-specific an-
tigen (PSA), and clinical staging to predict biochemical
failure. This risk stratification scheme has subsequently
been externally validated following treatment with these
same modalities.3,4 To our knowledge, no studies have
compared the preoperative risk stratification with out-
comes of men undergoing robot-assisted laparoscopic
prostatectomy (RALP).
Since its introduction in the United States in 2000, RALP
has become one of the most popular treatments for local-
ized prostate cancer. Although numerous reports of peri-
operative and short-term functional outcomes exist,5–10
due to the novel nature of robotics and the indolent
natural history of prostate cancer, there is a paucity of
literature on oncologic outcomes.10–12
In this study, we report the early oncologic outcomes in
patients who underwent RALP by a single surgeon over a
recent 4-year period. Specifically, we assess the associa-
tion between biochemical failure and perioperative vari-
ables, including D’Amico risk stratification in patients un-
dergoing RALP with up to 55 months of follow-up.
METHODS
Study Population
We queried an IRB-approved database of 802 consecutive
patients who underwent RALP by a single surgeon (DBS),
between January 2003 and November 2007. Patients with
insufficient clinical data to allow D’Amico risk stratifica-
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SCIENTIFIC PAPERtion were excluded from the current analysis. Addition-
ally, to ensure adequate oncologic follow-up, patients
with less than 6 months of documented PSA data were
also excluded, though all patients who failed biochemi-
cally prior to this time point were included.
Data Collection
Data collected in the database and assessed as part of the
current analysis include age at surgery, body mass index
(BMI, in kg/m
2), bladder neck involvement, margin status,
prostate weight, postoperative Gleason score, number of
nerve bundles spared, extra-capsular extension, capsular
invasion, tumor multi-centricity, perineural invasion, pres-
ence of high-grade prostatic intraepithelial neoplasia (HG-
PIN), seminal vesical involvement, and 1992 American
Joint Commission of Cancer Staging (AJCC) clinical and
pathologic cancer stage. BMI was calculated as weight in
kilograms divided by height in meters squared. Based on
clinical criteria, patients were stratified into risk categories
as defined by D’Amico: low (PSA 10, Gleason 7, and
AJCC stage cT2a or less); medium (PSA 20, Gleason 8,
or AJCC stage cT2b); high (PSA 20, Gleason 8, or AJCC
cT2c or higher). Margin status was defined as any focal or
multifocal involvement of tumor at the surgical margins on
a pathological specimen. Postoperatively, PSA levels were
determined at 6 weeks, and then again every 3 months for
the first year, then every 6 months for the next 3 years, and
then annually. The outcome for the current study was
biochemical failure defined as the first occurrence of a
postoperative PSA0.2 ng/mL.
Patient Care
In addition to a standard history and physical examina-
tion, all patients were evaluated preoperatively with PSA
level and digital rectal examination. Slides of prostate
needle biopsies were reviewed at our institution for con-
firmation of diagnosis and tumor grade. All patients with
PSA levels 10 ng/mL underwent nuclear bone scan and
computed tomography to evaluate for metastatic disease.
Patients with cT2 disease or those with tumor involvement
in all cores of a lateral side underwent endorectal MRI
examination for evaluation of nerve involvement. Surgi-
cally appropriate patients with clinically localized disease
were counseled regarding treatment options and offered
surgical intervention. Robotic prostatectomy was per-
formed by a single surgeon using a technique described
elsewhere.13 No patient received either androgen depri-
vation therapy or radiotherapy without prior biochemical
failure.
Statistical Analysis
Patient characteristics were calculated as means and prev-
alence for continuous and categorical variables, respec-
tively, by biochemical failure status. The statistical signif-
icance of differences across biochemical failure status was
determined using t tests for continuous variables and
chi-square tests for categorical variables. Next, the longi-
tudinal association between patient characteristics and
biochemical failure was determined. For patients with
biochemical failure, follow-up time was calculated as the
number of months between their RALP and the first sub-
sequent date when the patient had a PSA of 0.2 ng/mL.
For patients without a PSA 0.2 ng/mL during follow-up
(ie, those who remained free of biochemical failure), fol-
low-up time was calculated as the number of months
between RALP and their last PSA measurement. Biochem-
ical disease-free survival was graphed according to
D’Amico risk categories using the Kaplan-Meier method.
The statistical significance of differences in biochemical
disease-free survival across risk categories was deter-
mined using the log-rank test. Hazard ratios of biochem-
ical failure were determined for patient characteristics via
Cox proportional hazards regression models. Initially, un-
adjusted hazard ratios were calculated. Subsequently,
multivariable hazard ratios were calculated by including
postoperative Gleason score, extracapsular extension,
positive margins, perineural invasion, and D’Amico risk
category in an adjusted regression model. Due to colin-
earity with other variables, preoperative PSA and preop-
erative Gleason scores were not included in the multiva-
riable adjusted model. Finally, we determined the area
under the receiver operating characteristic (ROC) curve
for how well risk categories at the time of RALP discrim-
inate between patients who subsequently had and did not
have a biochemical failure during follow-up. In an ROC
curve, the true positive rate (sensitivity) is plotted as a
function of the false-positive rate (100% - specificity) for
different cut-off points of a test (ie, in this study, risk
categories) providing a measure of the overall ability of a
test to discriminate between cases of disease (ie, in this
study, biochemical failure) and controls. Each point on a
ROC curve represents a sensitivity/specificity pair corre-
sponding to a particular risk category. In a test with the
perfect ability to predict biochemical failure, the ROC
curve will pass through the upper left corner (100% sen-
sitivity, 100% specificity) of the plot. Therefore, the closer
the ROC plot is to the upper left corner, the higher the
overall accuracy of a test. A diagonal line on a plot (ie, the
reference line from the bottom left to top right corner)
represents a predictive test with the ability to detect out-
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Characteristics of Patients by Failure Status
Patient Characteristics Patients Without Failure
(n  430)
Patients With Failure
(n  34)
P-Value
Age*, years 59.2 (0.3) 60.4 (1.5) 0.46
Body mass index*, kg/m
2 27.0 (0.2) 26.8 (0.5) 0.71
Preop PSA
10 93% 74% 0.01
10–19 6% 21%
20 1% 6%
Preop Gleason sum
6 61% 24% 0.01
7 33% 59%
84 % 9 %
92 % 9 %
Preop clinical stage T1c 72.6% 79.4% 0.43
Pathologic weight† 46 (38 - 60) 41 (33 - 60) 0.26
Postop Gleason sum
6 33% 6% 0.01
7 60% 67%
8 4% 12%
9 3% 15%
Nerve sparing‡ 12% 23% 0.16
Extracapsular extension‡ 15% 34% 0.01
Capsule invasion
0 43% 34% 0.14
1 42% 38%
2 14% 28%
Multi-centricity 67% 63% 0.70
Margin positive 17% 39% 0.01
Bladder beck invasion 2% 6% 0.21
Peri-neural invasion 63% 87% 0.01
High grade PIN 87% 94% 0.41
D’Amico risk category
Low 58% 15% 0.01
Medium 35% 62%
High 7% 24%
*Mean (standard error).
†Median (25th to 75th percentiles).
‡Nerve sparing and extracapsular extension were dichotomized as yes or no.
JSLS (2009)13:515–521 517comes consistent with random chance and an area under
the curve value of 0.5. Values of the area under the curve
0.5 represent a test with discrimination better than
chance. Statistical significance was defined as any P0.05.
Analyses were performed using SAS (version 9.1, Cary,
NC) and Stata (version 10.0, College Station, TX).
RESULTS
Between January 2003 and November 2007, 802 patients
underwent RALP for clinically localized prostate cancer.
After initially excluding 284 patients (35.4%) for insuffi-
cient PSA follow-up, an additional 54 (6.7%) were re-
moved for lack of preoperative PSA documentation. The
remaining 464 patients were included in the study. Of the
284 excluded patients, 219 had enough data for D’Amico
risk stratification. In a separate analysis, the characteristics
of these excluded patients were compared with those of
the patients included in the analysis. There were no sig-
nificant differences in age, preoperative PSA, pathological
weight, D’Amico risk stratification, proportion of patients
with extracapsular extension, HGPIN, perineural invasion,
tumor multicentricity, margin status, Gleason score,
pathological or clinical stage between patients included in
and those excluded from the study (all P0.20); however,
a significantly higher proportion of patients in the in-
cluded analysis had bladder neck involvement over those
who were excluded (2.7% vs. 0%, respectively, P0.01)
(data not shown).
Of the 464 patients included in the study, mean/median
(range) follow-up was 14.1/11.6 (range, 6.0 to 55.3)
months. Overall, 256 (55%), 171 (37%), and 37 (8%) pa-
tients were categorized as having low-, medium-, and
high-risk disease by D’Amico criteria, respectively. Thirty-
four of 464 patients (7.3%) experienced biochemical fail-
ure at a mean/median (range) of 9.5/7.5 (range, 1 to 42.6)
months following surgery.
Table 1 illustrates characteristics of patients for those who
did and did not have biochemical failure during follow-
up. Biopsy Gleason score, PSA, extracapsular extension,
postoperative Gleason score, margin status, perineural
invasion, and D’Amico risk classification were each asso-
ciated with failure (all P0.05). Age, BMI, clinical stage,
pathological weight, nerve sparing, capsular invasion,
multicentricity, bladder neck invasion, and presence of
HGPIN were not significantly associated with biochemical
failure during follow-up. Actuarial BDFS at 30 months
for patients in the low-, medium- and high-risk stratifi-
cation categories were 94%, 79%, and 73%, respectively
(Figure 1).
In a univariate time-to-event analysis, higher preoperative
PSA, preoperative Gleason score, postoperative Gleason
score, the presence of extracapsular extension, positive
margins, peri-neural invasion, and medium and high
D’Amico risk categories were associated with an increased
hazard ratio of biochemical failure (Table 2). When con-
trolling for these variables in multivariable analysis,
D’Amico risk stratification was significantly associated
with biochemical failure, with hazard ratios of 5.04 (95%:
1.52 to 16.7; P0.001) and 7.04 (95%: 1.39 to 35.6;
P0.001) for medium- and high-risk categories compared
with low-risk categories, respectively. No statistically sig-
nificant difference was found between the outcomes of
high-risk patients compared with those of intermediate
risk; the hazard ratio was 1.65 (95%: 0.49 to 5.53;
P0.415). Margin status, postoperative Gleason score, ex-
tracapsular extension, and perineural invasion were not
associated with failure in the multivariate model.
The strength of D’Amico risk stratification in predicting
biochemical failure is depicted in a receiver operator char-
acteristic curve (Figure 2). The area under the curve for
this variable was 0.74, suggesting reasonably good dis-
criminatory power for predicting biochemical failure.
DISCUSSION
We report biochemical failure in 34 of 464 patients (7.3%)
undergoing RALP with a mean (range) follow-up time of
14.1 (6 to 55.3). In our cohort, D’Amico risk stratification
was associated with biochemical failure. Actuarial 30-
month BDFS rates were 94%, 79%, and 73%, for low-,
medium-, and high-risk patients, respectively. Our study
supports the D’Amico risk stratification as an effective
predictor of early outcomes following RALP. This is in
accord with several recent external validations of the risk
formula using large open radical prostatectomy cohorts.
Figure 1. Kaplan-Meier curve showing risk of BDFS over time in
low-, medium-, and high-risk patients. P0.001.
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and 68% from 7591 low-, medium-, and high-risk patients,
respectively. Another group from Johns Hopkins4 pub-
lished their data on 6652 men, showing 5-year BDFS rates
of 94.5%, 76.6%, and 54.6%, in the 3 respective risk
groups. The University of California San Francisco group14
documented 78%, 63%, and 60% 5-year BDFS rates in their
cohort of 1701 men registered in the CapSURE database.
In this latter study, while low-risk BDFS was significantly
better than those of intermediate- and higher-risk patients,
the group noted no significant difference in outcomes
between the latter 2 groups. We report a similar statisti-
cally insignificant trend towards worse BDFS in high-risk
over intermediate-risk patients; however, with only 8% of
our cohort having high-risk disease, we are limited in
supporting any conclusions regarding the predictive abil-
ity of intermediate- versus high-risk classification. We can,
however, conclude that in accordance with the above-
mentioned reports, our study also found D’Amico risk
stratification to be predictive of biochemical recurrence.
Although our cohort is substantially smaller than the men-
tioned studies, and our follow-up is significantly shorter,
to our knowledge, our study is the first to evaluate the
significance of risk stratification on early outcomes in a
robotic cohort.
While no RALP series has yet reported oncologic out-
comes using the D’Amico risk stratification, a few studies
Table 2.
Hazard Ratio of Failure Associated With Patient Characteristics
Characteristics Unadjusted Multivariate-
Adjusted§
Preop PSA
10 1.00 (ref) -
10–19 4.36 (1.88–10.1)
* -
20 8.38 (1.96–35.8)
* -
Preop Gleason sum
6 1.00 (ref) -
7 3.99 (1.75–9.07)
† -
8 3.93 (1.03–15.0)
‡ -
9 8.99 (2.37–34.1)
† -
Postop Gleason sum
5 or 6 1.00 (ref) 1.00 (ref)
7 5.57 (1.31–23.7)
‡ 1.38 (0.26–7.34)
8 11.3 (2.07–62.4)
† 1.98 (0.27–14.7)
9 19.3 (3.73–99.7)
* 1.62 (0.18–14.6)
Extracapsular extension 2.46 (1.18–5.13)
‡ 1.13 (0.51–2.47)
Margin positive 2.73 (1.35–5.54)
† 1.87 (0.84–4.14)
Perineural invasion 3.72 (1.30–10.7)
‡ 1.71 (0.55–5.36)
D’Amico risk category
Low 1.00 (ref) 1.00 (ref)
Medium 6.07 (2.29–16.1)
* 5.04 (1.52–16.7)
†
High 10.4 (3.37–31.8)
* 7.04 (1.39–35.6)
‡
*P0.001.
†P0.01.
‡P0.05.
§Variables not included in regression model for characteristics without data presented (-). Multivariate model includes all variables in
the same regression model.
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RALP. In the largest series to date, the Henry Ford group12
reports outcomes of 2766 patients. At a median (range)
follow-up time of 22 months (range, 7 to 71), the group
reports a 7.3% PSA recurrence rate, coincidentally identi-
cal to our overall recurrence rate. The Cornell group
reports11 4 failures in 132 men (3%) after 1 year of follow-
up. Patel and colleagues10 reported their experience with
their initial 200 cases and report a PSA recurrence rate of
5% at an average follow-up time of 9.7 months. Although
the authors do not comment on risk stratification specifi-
cally, they note that neither patients with pT2 disease nor
those with pT3a disease and focally extracapsular exten-
sion experienced recurrence during their brief follow-up.
The University of Chicago group15 also reported their
experiences and noted an overall biochemical recurrence
rate of 4.8% in 945 patients after a median follow-up of
15.6 months. The paper reports specifically on the signif-
icance of BMI on outcomes; in accordance with our re-
sults, the authors report no association between recur-
rence and BMI.
The greatest limitation in our study is the follow-up time,
which was only 14.1 months. Although prior studies have
shown disease progression can occur up to 15 years fol-
lowing diagnosis of untreated disease, over 90% of bio-
chemical recurrences following radical prostatectomy are
reported to occur within the first 5 years following sur-
gery.16,17 In addition, it is acknowledged that BDFS is a
surrogate, but not a substitute for the more clinically
relevant outcome of overall disease-specific survival. As
the field of robotic prostate surgery matures, 5-year out-
comes of large cohorts are imminent; however, until then,
these early outcomes offer useful information to consider
when counseling patients and deciding on treatment.
In our study, although margin status was associated with
outcome in a univariate analysis, a multivariate regression
model shows no significant association between margins
and biochemical failure. However, this may be an artifact
of the statistics, as margin positivity may be associated
with risk category. Thus, we can not discount the role of
significance of margins on biochemical failure in our co-
hort. Overall, we experienced an 18.8% positive margin
rate, including patients of all pathologic stages. The over-
all rate of margin positivity in published RALP studies is
variable (range, 2% to 59%), depending on surgeon expe-
rience, cohort size, and distribution of pathologic stages.18
Contemporary large series from experienced surgeons
report positive margin rates ranging from 10.5% to
17.3%.10,12,19–22 The significance of positive margins is
unclear. In the open prostatectomy literature, studies can
be found supporting or refuting the association between
positive margins and oncologic outcomes. While margin
location and extent of margin involvement are beyond the
scope of this article, studies have also suggested these
variables to also be associated with risk profile and bio-
chemical failure.22,23 As more outcomes are published, it
would be of great interest to further examine the signifi-
cance of such findings in patients undergoing RALP.
CONCLUSION
We report a 7.3% rate of biochemical failure at a mean of
14.1 months of follow-up after RALP in 464 patients. Our
early oncologic outcomes were significantly associated
with D’Amico risk stratification and clinical stage and
appear to be similar to oncologic outcomes of larger
radical prostatectomy series.
References:
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA
Cancer J Clin. 2008;58:71–96.
2. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochem-
ical outcome after radical prostatectomy, external beam radia-
tion therapy, or interstitial radiation therapy for clinically local-
ized prostate cancer. JAMA. 1998;280:969–974.
3. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML.
Mayo Clinic validation of the D’amico risk group classification
Figure 2. Receiver operator characteristic curve showing the
strength of D’Amico risk stratification in predicting biochemical
failure.
Risk Stratification and Early Oncologic Outcomes Following Robotic Prostatectomy, Akhavan A et al.
JSLS (2009)13:515–521 520for predicting survival following radical prostatectomy. J Urol.
2008;179:1354–1361.
4. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contempo-
rary evaluation of the D’amico risk classification of prostate
cancer. Urology. 2007;70:931–935.
5. Mikhail AA, Orvieto MA, Billatos ES, et al. Robotic-assisted
laparoscopic prostatectomy: first 100 patients with one year of
follow-up. Urology. 2006;68:1275–1279.
6. Menon M, Shrivastava A, Kaul S, et al. Vattikuti Institute
prostatectomy: contemporary technique and analysis of results.
Eur Urol. 2007;51:648–657.
7. Ahlering TE, Skarecky D, Lee D, Clayman RV. Successful
transfer of open surgical skills to a laparoscopic environment
using a robotic interface: initial experience with laparoscopic
radical prostatectomy. J Urol. 2003;170:1738–1741.
8. Box GN, Ahlering TE. Robotic radical prostatectomy: long-
term outcomes. Curr Opin Urol. 2008;18:173–179.
9. Lee DI, Eichel L, Skarecky DW, Ahlering TE. Robotic lapa-
roscopic radical prostatectomy with a single assistant. Urology.
2004;63:1172–1175.
10. Patel VR, Tully AS, Holmes R, Lindsay J. Robotic radical
prostatectomy in the community setting–the learning curve and
beyond: initial 200 cases. J Urol. 2005;174:269–272.
11. Herman MP, Raman JD, Dong S, Samadi D, Scherr DS.
Increasing body mass index negatively impacts outcomes fol-
lowing robotic radical prostatectomy. JSLS. 2007;11:438–442.
12. Badani KK, Kaul S, Menon M. Evolution of robotic radical
prostatectomy: assessment after 2766 procedures. Cancer. 2007;
110:1951–1958.
13. Raman JD, Dong S, Levinson A, Samadi D, Scherr DS. Ro-
botic radical prostatectomy: operative technique, outcomes, and
learning curve. JSLS. 2007;11:1–7.
14. Mitchell JA, Cooperberg MR, Elkin EP, et al. Ability of 2
pretreatment risk assessment methods to predict prostate cancer
recurrence after radical prostatectomy: data from CaPSURE.
J Urol. 2005;173:1126–1131.
15. Wiltz AL, Shikanov S, Eggener SE, et al. Robotic radical
prostatectomy in overweight and obese patients: oncological
and validated-functional outcomes. Urology. 2009;73:316–322.
16. Johansson JE, Andren O, Andersson SO, et al. Natural history
of early, localized prostate cancer. JAMA. 2004;291:2713–2719.
17. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM,
Scardino PT. A preoperative nomogram for disease recurrence
following radical prostatectomy for prostate cancer. J Natl Can-
cer Inst. 1998;90:766–771.
18. Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W.
Evidence from robot-assisted radical prostatectomy: a systematic
review. Eur Urol. 2007;51:45–56.
19. Costello AJ, Haxhimolla H, Crowe H, Peters JS. Installation of
telerobotic surgery and initial experience with telerobotic radical
prostatectomy. BJU Int. 2005;96:34–38.
20. Joseph JV, Rosenbaum R, Madeb R, Erturk E, Patel HR.
Robotic extraperitoneal radical prostatectomy: an alternative ap-
proach. J Urol. 2006;175:945–951.
21. Van Appledorn S, Bouchier-Hayes D, Agarwal D, Costello
AJ. Robotic laparoscopic radical prostatectomy: setup and pro-
cedural techniques after 150 cases. Urology. 2006;67:364–367.
22. Smith JA Jr, Chan RC, Chang SS, et al. A comparison of the
incidence and location of positive surgical margins in robotic
assisted laparoscopic radical prostatectomy and open retropubic
radical prostatectomy. J Urol. 2007;178:2385–2390.
23. Vis AN, Schroder FH, van der Kwast TH. The actual value of
the surgical margin status as a predictor of disease progression in
men with early prostate cancer. Eur Urol. 2006;50:258–265.
JSLS (2009)13:515–521 521